{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:44:12Z","timestamp":1792629852189,"version":"4.5.0"},"reference-count":39,"publisher":"MyJove Corporation","issue":"151","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/59368","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T20:00:19Z","timestamp":1568318419000},"source":"Crossref","is-referenced-by-count":4,"title":["An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis"],"prefix":"10.3791","author":[{"given":"Xiaoqiang","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Schepers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Avella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Kimchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussuf T.","family":"Kaifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Staveley-O'Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"ref1","first-page":"517","type":"journal-article","article-title":"Hepatocellular carcinoma - United States","volume":"59","author":"O'Connor","year":"2010","unstructured":"O\u2019Connor, S., Ward, J.W. Hepatocellular carcinoma \u2013 United States, 2001-2006. Morbidity and Mortality Weekly Report. 59, 517-520 (2010).","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","type":"journal-article","article-title":"Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030","volume":"34","author":"Petrick","year":"2016","unstructured":"Petrick, J., Kelly, S., Altekruse, S., McGlynn, K., Rosenberg, P. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 34, 1787-1794 (2016).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","type":"journal-article","article-title":"Targeted and Immune-based Therapies for Hepatocellular Carcinoma","volume":"156","author":"Greten","year":"2019","unstructured":"Greten, T., Lai, C., Li, G., Staveley-O\u2019Carroll, K. Targeted and Immune-based Therapies for Hepatocellular Carcinoma. Gastroenterology. 156, 510-524 (2019).","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","type":"journal-article","article-title":"Hepatocellular Carcinoma","volume":"2","author":"Llovet","year":"2016","unstructured":"Llovet, J., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., Gores, G. Hepatocellular Carcinoma. Nature reviews. Disease primers. 2, 16018 (2016).","journal-title":"Nature reviews. Disease primers"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"55715","DOI":"10.18632\/oncotarget.18382","type":"journal-article","article-title":"Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy","volume":"8","author":"Ding","year":"2017","unstructured":"Ding, X., et al. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 8, 55715-55730 (2017).","journal-title":"Oncotarget"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jhep.2017.05.004","type":"journal-article","article-title":"Controlling liver cancer mortality on a global scale: still a long way to go","volume":"67","author":"Colombo","year":"2017","unstructured":"Colombo, M., Maisonneuve, P. Controlling liver cancer mortality on a global scale: still a long way to go. Journal of Hepatology. 67, 216-217 (2017).","journal-title":"Journal of Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","type":"journal-article","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","unstructured":"Llovet, J., Burroughs, A., Bruix, J. Hepatocellular carcinoma. Lancet. 362 1907-1917 (2003).","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","type":"journal-article","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","unstructured":"Parkin, D., Bray, F., Ferlay, J., Pisani, P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 94, 153-156 (2001).","journal-title":"International Journal of Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.2005.03.196","type":"journal-article","article-title":"Hepocellular carcinoma: the need for progress","volume":"23","author":"Thomas","year":"2005","unstructured":"Thomas, M., Zhu, A. Hepocellular carcinoma: the need for progress. Journal of Clinical Oncology. 23, 2892-2899 (2005).","journal-title":"Journal of Clinical Oncology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","type":"journal-article","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2008","unstructured":"Llovet, J., Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48, 1312-1327 (2008).","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","type":"journal-article","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","unstructured":"Bruix, J., Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology. 53, 1020-1022, doi: 10.1002\/hep.24199 (2011).","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4254\/wjh.v7.i2.245","type":"journal-article","article-title":"Surgical management of hepatocellular carcinoma","volume":"7","author":"Pang","year":"2015","unstructured":"Pang, T., Lam, V. Surgical management of hepatocellular carcinoma. World Journal of Hepatology. 7, 245-252 (2015).","journal-title":"World Journal of Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","type":"journal-article","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","unstructured":"Llovet, J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institution. 100, 698-711 (2008).","journal-title":"Journal of the National Cancer Institution"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1126\/science.348.6230.54","type":"journal-article","article-title":"Cancer immunology and immunotherapy. Realizing the promise. Introduction","volume":"348","author":"Mueller","year":"2015","unstructured":"Mueller, K. Cancer immunology and immunotherapy. Realizing the promise. Introduction. Science. 348, 54-55 (2015).","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","type":"journal-article","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","unstructured":"Gajewski, T., Schreiber, H., Fu, Y. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 14, 1014-1022 (2013).","journal-title":"Nature Immunology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.coi.2013.02.011","type":"journal-article","article-title":"Combining cancer immunotherapy and targeted therapy","volume":"25","author":"Ribas","year":"2013","unstructured":"Ribas, A., Wolchok, J. Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology. 25, 291-296 (2013).","journal-title":"Current Opinion in Immunology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","type":"journal-article","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","unstructured":"Postow, M., Callahan, M., Wolchok, J. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 33, 1974-1982 (2015).","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","type":"journal-article","article-title":"VISTA is an inhibitory immune checkpoint that is increased in ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","unstructured":"Gao, J., et al. VISTA is an inhibitory immune checkpoint that is increased in ipilimumab therapy in patients with prostate cancer. Nature Medicine. 23, 551-555 (2017).","journal-title":"Nature Medicine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/imt-2017-0024","type":"journal-article","article-title":"The future of immune checkpoint cancer therapy after PD-1 and CTLA-4","volume":"9","author":"Hahn","year":"2017","unstructured":"Hahn, A., Gill, D., Pal, S., Agarwal, N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 9, 681-692 (2017).","journal-title":"Immunotherapy"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CCO.0000000000000351","type":"journal-article","article-title":"Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer","volume":"29","author":"Remon","year":"2017","unstructured":"Remon, J., Besse, B. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Current Opinion in Oncology. 29, 97-104 (2017).","journal-title":"Current Opinion in Oncology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000449342","type":"journal-article","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: 2017 update","volume":"6","author":"Kudo","year":"2017","unstructured":"Kudo, M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer. 6, 1-12 (2017).","journal-title":"Liver Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","type":"journal-article","article-title":"Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials","volume":"92","author":"Kudo","year":"2017","unstructured":"Kudo, M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials. Oncology. 92, 50-62 (2017).","journal-title":"Oncology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2010.10.013","type":"journal-article","article-title":"Potential of immunotherapy for hepatocellular carcinoma","volume":"54","author":"Breous","year":"2011","unstructured":"Breous, E., Thimme, R. Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology. 54, 830-834 (2011).","journal-title":"Journal of Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2013.04.002","type":"journal-article","article-title":"Facing the dawn of immunotherapy for hepatocellular carcinoma","volume":"59","author":"Sprinzl","year":"2013","unstructured":"Sprinzl, M., Galle, P. Facing the dawn of immunotherapy for hepatocellular carcinoma. Journal of Hepatology. 59, 9-10 (2013).","journal-title":"Journal of Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4172\/2155-9899.1000376","type":"journal-article","article-title":"Immune-based therapy clinical trials in hepatocellular carcinoma","volume":"6","author":"Liu","year":"2015","unstructured":"Liu, D., Staveley-O\u2019Carroll, K., Li, G. Immune-based therapy clinical trials in hepatocellular carcinoma. Journal of Clinical Cell Immunology. 6, 376 (2015).","journal-title":"Journal of Clinical Cell Immunology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/gutjnl-2014-307990","type":"journal-article","article-title":"Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches","volume":"64","author":"Greten","year":"2015","unstructured":"Greten, T., Wang, X., Korangy, F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 64, 842-848 (2015).","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CCO.0000000000000221","type":"journal-article","article-title":"Recent developments and future challenges in immune checkpoint inhibitory cancer treatment","volume":"27","author":"Koster","year":"2015","unstructured":"Koster, B., de Gruijl, T., van den Eertwegh, A. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Current Opinion in Oncology. 27, 482-488 (2015).","journal-title":"Current Opinion in Oncology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","type":"journal-article","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","unstructured":"Johnson, D., Sullivan, R., Menzies, A. Immune checkpoint inhibitors in challenging populations. Cancer. 123, 1904-1911 (2017).","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29360","type":"journal-article","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with an mTOR inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","unstructured":"Li, H., et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with an mTOR inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 66, 1920-1933 (2017).","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2613.2009.00656.x","type":"journal-article","article-title":"Experimental mouse models for hepatocellular carcinoma research","volume":"90","author":"Heindryckx","year":"2009","unstructured":"Heindryckx, F., Colle, I., van Vlierberghe, H. Experimental mouse models for hepatocellular carcinoma research. International Journal of Experimental Pathology. 90, 367-386 (2009).","journal-title":"International Journal of Experimental Pathology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4172\/2155-9899.1000438","type":"journal-article","article-title":"Development of inCVAX, in situ cancer vaccine, and its immune response in mice with hepatocellular cancer","volume":"7","author":"Qi","year":"2016","unstructured":"Qi, X., et al. Development of inCVAX, in situ cancer vaccine, and its immune response in mice with hepatocellular cancer. Journal of Clinical and Cellular Immunology. 7, 438 (2016).","journal-title":"Journal of Clinical and Cellular Immunology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1080\/15384047.2015.1095412","type":"journal-article","article-title":"Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer","volume":"16","author":"Qi","year":"2015","unstructured":"Qi, X., et al. Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer. Cancer Biology and Therapy. 16, 1812-1819 (2015).","journal-title":"Cancer Biology and Therapy"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1372079","DOI":"10.1080\/2162402X.2017.1372079","type":"journal-article","article-title":"Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer","volume":"7","author":"Liu","year":"2017","unstructured":"Liu, D., et al. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology. 7, e1372079 (2017).","journal-title":"Oncoimmunology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4049\/jimmunol.171.2.697","type":"journal-article","article-title":"In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice","volume":"171","author":"Staveley-O'Carroll","year":"2003","unstructured":"Staveley-O\u2019Carroll, K., et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. Journal of Immunology. 171, 697-707 (2003).","journal-title":"Journal of Immunology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hep.24652","type":"journal-article","article-title":"Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model","volume":"55","author":"Avella","year":"2012","unstructured":"Avella, D., et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology. 55, 141-152 (2012).","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2016.07.044","type":"journal-article","article-title":"Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model","volume":"66","author":"Li","year":"2017","unstructured":"Li, G., et al. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. Journal of Hepatology. 66, 75-85 (2017).","journal-title":"Journal of Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2017.10.050","type":"journal-article","article-title":"Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in ice","volume":"154","author":"Li","year":"2018","unstructured":"Li, G., et al. Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in ice. Gastroenterology. 154, 1024-1036.e9 (2018).","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/j.1460-2075.1989.tb03363.x","type":"journal-article","article-title":"T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein\/SV40 T antigen hybrid gene","volume":"8","author":"Held","year":"1989","unstructured":"Held, W., et al. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein\/SV40 T antigen hybrid gene. EMBO Journal. 8, 183-191 (1989).","journal-title":"EMBO Journal"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","type":"journal-article","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","unstructured":"Hanahan, D., Weinber, R. Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011).","journal-title":"Cell"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/59368\/an-oncogenic-hepatocyte-induced-orthotopic-mouse-model-hepatocellular","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:20:09Z","timestamp":1792628409000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/59368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":39,"journal-issue":{"issue":"151","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3791\/59368","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}